$0.5558
+0.03
(+6.48%)▲
Insights on Sangamo Therapeutics, Inc.
Revenue is down for the last 2 quarters, 9.39M → 2.04M (in $), with an average decrease of 78.3% per quarter
Netprofit is up for the last 3 quarters, -114.50M → -60.29M (in $), with an average increase of 41.3% per quarter
In the last 1 year, Novo Nordisk A/s has given 53.4% return, outperforming this stock by 112.5%
6.79%
Downside
Day's Volatility :6.79%
Upside
0.0%
48.02%
Downside
52 Weeks Volatility :82.57%
Upside
66.47%
Period | Sangamo Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -0.75% | -0.8% | 0.0% |
6 Months | 25.86% | 10.5% | 0.0% |
1 Year | -59.13% | 6.4% | 2.9% |
3 Years | -94.81% | 14.6% | -21.3% |
Market Capitalization | 108.1M |
Book Value | $0.47 |
Earnings Per Share (EPS) | -1.48 |
PEG Ratio | 0.0 |
Wall Street Target Price | 3.5 |
Profit Margin | -146.3% |
Operating Margin TTM | -2476.15% |
Return On Assets TTM | -17.6% |
Return On Equity TTM | -136.47% |
Revenue TTM | 176.2M |
Revenue Per Share TTM | 1.01 |
Quarterly Revenue Growth YOY | -92.5% |
Gross Profit TTM | -138.6M |
EBITDA | -87.4M |
Diluted Eps TTM | -1.48 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.5 |
EPS Estimate Next Year | -0.27 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.11 |
What analysts predicted
Upside of 529.72%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 84.5M | ↑ 130.95% |
Net Income | -68.3M | ↑ 25.23% |
Net Profit Margin | -80.91% | ↑ 68.32% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 102.4M | ↑ 21.29% |
Net Income | -75.8M | ↑ 10.95% |
Net Profit Margin | -74.02% | ↑ 6.89% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 118.2M | ↑ 15.39% |
Net Income | -121.1M | ↑ 59.75% |
Net Profit Margin | -102.48% | ↓ 28.46% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 110.7M | ↓ 6.34% |
Net Income | -178.3M | ↑ 47.2% |
Net Profit Margin | -161.06% | ↓ 58.58% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 111.3M | ↑ 0.54% |
Net Income | -192.3M | ↑ 7.84% |
Net Profit Margin | -172.76% | ↓ 11.7% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 176.2M | ↑ 58.34% |
Net Income | -257.8M | ↑ 34.09% |
Net Profit Margin | -146.3% | ↑ 26.46% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 26.5M | ↓ 9.93% |
Net Income | -53.2M | ↑ 23.12% |
Net Profit Margin | -200.89% | ↓ 53.93% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 27.2M | ↑ 2.91% |
Net Income | -52.0M | ↓ 2.22% |
Net Profit Margin | -190.87% | ↑ 10.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 158.0M | ↑ 480.08% |
Net Income | 21.1M | ↓ 140.66% |
Net Profit Margin | 13.38% | ↑ 204.25% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.8M | ↓ 95.67% |
Net Income | -114.5M | ↓ 641.84% |
Net Profit Margin | -1.7K% | ↓ 1688.67% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.4M | ↑ 37.5% |
Net Income | -104.2M | ↓ 9.03% |
Net Profit Margin | -1.1K% | ↑ 566.94% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.0M | ↓ 78.27% |
Net Income | -60.3M | ↓ 42.11% |
Net Profit Margin | -3.0K% | ↓ 1844.44% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 590.4M | ↑ 105.9% |
Total Liabilities | 223.9M | ↑ 126.5% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 637.5M | ↑ 7.98% |
Total Liabilities | 204.8M | ↓ 8.53% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 938.6M | ↑ 47.22% |
Total Liabilities | 441.2M | ↑ 115.45% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 721.9M | ↓ 23.08% |
Total Liabilities | 346.6M | ↓ 21.44% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 562.5M | ↓ 22.08% |
Total Liabilities | 267.6M | ↓ 22.8% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 165.3M | ↓ 70.61% |
Total Liabilities | 82.4M | ↓ 69.19% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 593.9M | ↓ 3.76% |
Total Liabilities | 284.8M | ↓ 4.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 562.5M | ↓ 5.29% |
Total Liabilities | 267.6M | ↓ 6.04% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 440.6M | ↓ 21.68% |
Total Liabilities | 105.0M | ↓ 60.77% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 325.1M | ↓ 26.21% |
Total Liabilities | 91.4M | ↓ 12.89% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 219.7M | ↓ 32.42% |
Total Liabilities | 84.8M | ↓ 7.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 165.3M | ↓ 24.75% |
Total Liabilities | 82.4M | ↓ 2.76% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 37.2M | ↑ 232.34% |
Investing Cash Flow | -178.1M | ↑ 120.14% |
Financing Cash Flow | 231.7M | ↑ 137.67% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -144.4M | ↓ 488.68% |
Investing Cash Flow | -59.8M | ↓ 66.42% |
Financing Cash Flow | 142.0M | ↓ 38.7% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 169.9M | ↓ 217.64% |
Investing Cash Flow | -271.6M | ↑ 354.22% |
Financing Cash Flow | 153.1M | ↑ 7.79% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -233.3M | ↓ 237.31% |
Investing Cash Flow | 248.2M | ↓ 191.37% |
Financing Cash Flow | 32.9M | ↓ 78.54% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -223.6M | ↓ 4.13% |
Investing Cash Flow | 59.3M | ↓ 76.11% |
Financing Cash Flow | 84.7M | ↑ 157.65% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -53.6M | ↓ 0.68% |
Investing Cash Flow | -13.5M | ↓ 147.35% |
Financing Cash Flow | 43.8M | ↑ 91.56% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -57.0M | ↑ 6.4% |
Investing Cash Flow | 42.6M | ↓ 416.54% |
Financing Cash Flow | 19.5M | ↓ 55.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -66.3M | ↑ 16.22% |
Investing Cash Flow | 35.7M | ↓ 16.16% |
Financing Cash Flow | 8.0M | ↓ 59.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -60.7M | ↓ 8.43% |
Investing Cash Flow | 42.5M | ↑ 18.86% |
Financing Cash Flow | 6.5M | ↓ 18.53% |
Sell
Neutral
Buy
Sangamo Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Sangamo Therapeutics, Inc. | -3.29% | 25.86% | -59.13% | -94.81% | -94.81% |
Moderna, Inc. | 22.23% | 73.44% | -6.95% | -27.99% | 361.25% |
Regeneron Pharmaceuticals, Inc. | 2.13% | 14.97% | 26.94% | 97.25% | 178.01% |
Novo Nordisk A/s | -0.73% | 21.74% | 53.4% | 231.98% | 415.39% |
Vertex Pharmaceuticals Incorporated | -0.73% | 3.97% | 15.72% | 86.68% | 129.5% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Sangamo Therapeutics, Inc. | NA | NA | 0.0 | -0.5 | -1.36 | -0.18 | NA | 0.47 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Sangamo Therapeutics, Inc. | Buy | $108.1M | -94.81% | NA | -146.3% |
Moderna, Inc. | Buy | $41.7B | 361.25% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 178.01% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 415.39% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 129.5% | 28.81 | 36.68% |
BlackRock Inc
Vanguard Group Inc
Wasatch Advisors LP
Acadian Asset Management LLC
Citadel Advisors Llc
Geode Capital Management, LLC
Sangamo Therapeutics, Inc.’s price-to-earnings ratio stands at None
Read Morefor sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Organization | Sangamo Therapeutics, Inc. |
Employees | 405 |
CEO | Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. |
Industry | Health Technology |